

2. CENTER FOR PRE-CLINICAL RESEARCH

(CPCR)

Advance your goal to make sure your treatment reaches the patient







CENTER
FOR
PRE-CLINICAL
RESEARCH
(CPCR)

Advance your goal to make sure your treatment reaches the patient

Department of Pharmaceutical Technology

OUR THRUST AREAS

- 1) Toxicity Studies
- 2 Efficacy Studies
- 3 Pharmacokinetics Studies
- 4) BA/ BE Studies
- 5) IV IC Correlation
- 6) Model Development

FOR ENQUIRY CONTACT

MS GARIMA AGARWAL, ASSISTANT PROFESSOR HP: 9560347907; garima.agarwal@miet.ac.in

Dr. NITIN SHARMA, PROFESSOR HP: 6399000364; niti

A

MIET, N.H. 58, Delhi-Roorkee Highway, Baghpat Bypass Road Crossing, Meerut, Uttar Pradesh 250005

INDUSTRIES COVERED



Pharmaceuticals (small molecules, Biosimilar & Recombinant DNA products) & Alternate medicines



Veterinary drugs



Cosmetics



Botanicals



Food additives



2.1 Objectives of CPCR

Preclinical Research

The CPCR aims to conduct highquality pre-clinical studies to support the development of innovative medical treatments, including new drugs, devices, and therapeutic interventions.

Collaboration and Training

The CPCR fosters collaborations with academic institutions, pharmaceutical companies, and research organizations to advance scientific knowledge and provide training opportunities for students and researchers.

Advancing Medical Innovation

By conducting cutting-edge preclinical research, the CPCR aims to contribute to the development of innovative medical treatments and therapies that can improve patient outcomes and quality of

2.2 Coordinators & Team

S. No.	Status	Name	Mobile	Emai1
1	Coordinator	Ms. Garima Agarwal	9560347907	garima.agarwal@miet.ac.i n
2	Chairman IAEC	Dr. Vipin Kumar Garg	+ 9 1 - 9 7 1 9 5 64736	vipin.garg@miet.ac.in
3	S c i e n t i s t Incharge	Mr. Ankit Chaudhary	+ 9 1 - 7409597509	ankit.chaudhary@miet.ac.i n
4	Student	Mr. Prawal Gupta	+91-8171269595	Praval.gupta@miet.ac.in
	Ottadont	mir ramar dapta	01 01.120000	Travail gapta e i i i otta o i i i
5	Student	Mr. Nitin Kumar	+91-9520650981	Nitin.kumar@miet.ac.in




2. 3 OBJECTIVES





2. 4 CPCR OFFERS





2. 5 AREAS COVERED



INDUSTRIES COVERED



Pharmaceuticals (small molecules, Biosimilar, & Recombinant DNA products) & Alternate medicines



Veterinary drugs



Cosmetics

Botanicals



Food additives



2.6 Integrated Preclinical Research Platform

Model Systems

Rodents Animal
Models of Diseases



Scientific Objectives

Safety/ toxicity/ efficacy PoC, MoA, Drug Distribution,

Pharmacokinetics

Gross pathology & necropsy



Cell Culture

Expansion & passage Dissociate & aliquot GLP -

compliant

Reporting & Consulting
Medical Writing GLP, QA,
QC Presentations/journal
publications



Data & Endpoints

Histopathology Immunostaining Microimaging



ANIMAL HOUSE ACCREDITATION

Quality And Accreditation Institute Centre for Laboratory Accreditation





Certificate of Accreditation

MIET Animal House Facility & MIET Cell Culture Lab

(Meerut Institute of Engineering & Technology, City Educational and Social Welfare Society)

A Block, N.H. 58, Delhi-Roorkee Highway, Baghpat Road Bypass Crossing, Meerut-250005, Uttar Pradesh, India

has been assessed and accredited in accordance with the Standard
ISO/IEC 17025:2017

"General Requirements for the Competence of Testing and Calibration Laboratories"

In the field of

Testing

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued compliance to the above standard L any other requirements specified by QAI.



QAI/CLA/TL/2023/0028

Valid from: 10 October 2023

Valid until: 09 October 2025

Min

Dr. Bhupendra Kumar Rana Chief Executive Officer Whereand -=

Prof. Vikram Kumar Chair, CLA

User is advised to verify the current scope of accreditation by visiting our website: www.qai.org.in



No. 25/329/2011-AWD Government of India

Ministry of Fisheries, Animal Husbandry and Dairying
Department of Animal Husbandry and Dairying
O/o Committee for the purpose of Control and Supervision of Experiments on Animals
(CPCSEA)

Delhi Milk Scheme Complex, Shadipur, Delhi – 110008 Date: 03.01.2023

To,

Dr. Vipin Kumar Garg, Chairperson, IAEC
Meerut Institute of Engineering and Technology
Delhi Bypass Road, Baghpat Crossing, PO Malyana,
Meerut -250 002, Uttar Pradesh
Email: vipin.garg@miet.ac.in
Mobile: 9719564736

Subject: Renewal of Registration and Reconstitution of Institutional Animals Ethics Committee (IAEC)-regarding

Sir.

The registration of Animal House Facility of your establishment with CPCSEA has been renewed for a period of five years from the date of issue of this letter.

 The new registration number of Animal House Facility of your establishment is 711/PO/ReRC/8/02/CPCSEA for Research for Education purpose and Research for Commercial purpose on small animals. Henceforth, the new registration number may kindly be quoted in all your future correspondence.

Milt OUTCOME

S. No.	Date	Name of the Outcome (Publication / Presentation / Patent / Copyright / Product Developed etc.)	Title	Author(s) / Contributor(s)
1	2021 - 2023	Industrial Consultancy	Safety Profile and BA/BE studies of various Nutraceuticals, cosmeceuticals, and Medical Devices	Dr. Vipin Kumar Garg, Prof Alimuddin Saifi, Dr. Shweta Dumoga, Dr. Prabhash Nath Tripathi, Garima Agarwal, Ankit Chaudhary
2	2023	Publication	Effects of Mito-Q on cognitive and motor function in a rat model of Huntington's disease after 3-NPA-induced mitochondrial stress	Mr.Avnesh Kumar & Dr. Vipin Kumar Garg
3	2023	Publication	Preclinical evaluation of the anti- hyperglycemic activity of ethanolic extract of leaves of Scheffleraarboricola in an alloxan-induced diabetic	Avnesh Kumar & Dr. Vipin Kumar Garg
			animal model of rats	
4	2023	Publication	Cytotoxicity and bioavailability assessment from thiamin-phospholipid complexation loaded Ajwain oil based self nano emulsifying system	Anoop Kumar, Amulya Jindal, Piyush Kumar Singh Arya



NOTED RESEARH AT DOPT CENTRE FACILTIES

Project Name	Therapy	Area	TRL
Wound-healing patch for diabetic foot ulcers	Anti-Diabetics	Drug Delivery	Level 3
Design, Synthesis, and Evaluation of Combretastatin A-4 analogs as anti-cancer agents	Anti-Cancer	Novel Chemical Entity	Level 4
Design, Synthesis, and Evaluation of 4-Aminoquinazoline analogs as anti-cancer agents	Anti-Cancer	Novel Chemical Entity (Patent Granted)	Level 4
Design, Synthesis, and Evaluation of Quinazolinone analogs as anti-tubercular agents	Anti-infectives	Novel Chemical Entity	Level 4
Preparation of a novel herbal anthelmintic formulation	Anthelmintic	Formulation Development (Patent Granted)	Level 5
Novel Drug Delivery System of an antidiabetic for bioavailability enhancement	Anti-Diabetic	Drug Delivery	Level 4
Natural Polysaccharide based colon drug delivery	GI	Drug Delivery	Level 4
Nanoemulsion with enhanced behavioral performance in Parkinson's disease	CNS	Drug Delivery	Level 4
Nanostructured in-situ nasal gel for nose-to-brain targeting	CNS & CVS	Drug Delivery	Level 4

TRL: Technology Readiness Level; GI: Gastro-intestinal; CNS: Central Nervous System; CVS: Cardiovascular System



Project Name	Therapy	Area	TRL
An anti-asthmatic activity of natural Toll- like receptor-4 antagonist in OVA-LPS- induced asthmatic rats	Asthma	Novel Chemical Entity	Level 4
Role of TLR4 antagonist in OVA/LPS induced vasculitis in rats	Vasculitis	Novel Chemical Entity	Level 4
Protective role of selective anti-depressants and anti-diabetics against three nitro-propionic acid-induced cognitive dysfunction and behavioral impairment in Huntington's disease	CNS	Modeling	Level 4

DEVICES & DIAGNOSTICS

Project Name	Therapy Area	Patent Status	TRL
Development of an automated Cataract Detection & grading system	Ophthalmic	IP filed	Level 6
Development of an algorithm for the detection of ICP from ocular USG images	Ophthalmic	IP filed	Level 5
Development of smart automated Pill box dispenser for elderly patients	Patient Care	IP filed	Level 7
IOT-based Infusion pump	Patient care	NA	Level 6

TRL: Technology Readiness Level; ICP: Intracranial pressure; IoT: Internet of Things; IP: Indian patent; USG: Ultrasound; CNS: Central Nervous System

2. 9 MOU AND INDUSTRY CONSULTANCY

Total 5 MOU with Industry

- Mittal Global Clinical Trial Services
- Chemzin Labs Private Limited
- Cedrus Bio-products Private Limited
- AAL Biosciences Research Pvt. Ltd.
- MDC Pharmaceuticals Ltd
- Total Consultancy Projects

$$2022-2023 \quad -122 \quad (45 + 77)$$



2.10 Future Plans and Expansion

Expand Facilities

The CPCR plans to expand its facilities to accommodate growing research demands and accommodate new technologies.

Strengthen Partnerships

The CPCR aims to build stronger collaborations with leading institutions and industry partners to drive innovation and impact.

Increase Capabilities

The CPCR will continuously invest in the latest equipment and technologies to enhance its research capabilities and stay at the forefront of scientific advancements.

Enhance Training

The CPCR will offer increased training opportunities for students, researchers, and professionals to foster the next generation of scientific leaders.

THANK YOU